a public good project by the
Synthesis
Company
of California

© 2026

Antonio Omuro | doi.page

0 works0 citations0 h-index

Antonio Omuro

Yale New Haven Hospital(US)Palo Alto University(US)Yale University(US)Yale New Haven Health System(US)Palo Alto Institute(US)Stanford Medicine(US)Stanford Cancer InstituteStanford University(US)

Publications by Year

Research Areas

Glioma Diagnosis and Treatment, Brain Metastases and Treatment, CNS Lymphoma Diagnosis and Treatment, Lymphoma Diagnosis and Treatment, Radiomics and Machine Learning in Medical Imaging

Most-Cited Works

→ Tumor mutational load predicts survival after immunotherapy across multiple cancer types(2019)4,299 cited
→ Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients(2017)3,455 cited
→ OncoKB: A Precision Oncology Knowledge Base(2017)2,642 cited
→ Glioblastoma and Other Malignant Gliomas(2013)2,275 cited
→ Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma(2020)1,394 cited
→ Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study(2015)568 cited

→ Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome(2013)

481 cited

→ Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143(2017)480 cited

→ Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter(2022)467 cited

→ Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial(2022)451 cited